Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elias Haj-Yehia

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Heart Failure Reports|February 19, 2025
Prevention of cancer-therapy related cardiac dysfunctionElias Haj-Yehia, Lars Michel, Raluca I Mincu, et al.
British Journal of Pharmacology|March 11, 2026
Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio-oncology RegistryElias Haj-Yehia, Lisa Zimmer, Lena Lampe, et al.
International Journal of Cardiology. Heart & Vasculature|August 25, 2025
Hemoglobin is associated with cardiotoxicity in melanoma patients without anemia receiving immune checkpoint inhibitor therapyElias Haj-Yehia, Raluca I Mincu, Phillip Schulte, et al.
Journal of Visualized Experiments : Jove|October 13, 2025
Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence MicroscopySebastian Korste, Elias Haj-Yehia, Simon F Merz, et al.
Diabetes, Obesity & Metabolism|July 24, 2018
Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacitySebastian Diebold, Julia Moellmann, Florian Kahles, et al.
British Journal of Pharmacology|June 16, 2026
Refining the treatment of immune checkpoint inhibitor-associated myocarditis: Challenges, innovations and rechallenge considerationsRaluca I Mincu, Lisa Zimmer, Dimitra Vlachopoulou, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 13, 2023
High neutrophil-to-lymphocyte ratio is associated with cancer therapy-related cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapyElias Haj-Yehia, Raluca I Mincu, Sebastian Korste, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 29, 2026
Evaluation of neutrophil oxidative burst capacity in relation to major adverse cardiac events and infection in patients with cardiovascular diseaseElias Haj-Yehia, Phillip Schulte, Christian Fehring, et al.
International Journal of Molecular Sciences|April 13, 2023
Anthracycline Therapy Modifies Immune Checkpoint Signaling in the HeartSebastian Korste, Stephan Settelmeier, Lars Michel, et al.
Journal of Clinical Medicine|December 9, 2020
Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial InfarctionElias Haj-Yehia, Robert Werner Mertens, Florian Kahles, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Heart Failure Reports|February 19, 2025
Prevention of cancer-therapy related cardiac dysfunctionElias Haj-Yehia, Lars Michel, Raluca I Mincu, et al.
British Journal of Pharmacology|March 11, 2026
Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio-oncology RegistryElias Haj-Yehia, Lisa Zimmer, Lena Lampe, et al.
International Journal of Cardiology. Heart & Vasculature|August 25, 2025
Hemoglobin is associated with cardiotoxicity in melanoma patients without anemia receiving immune checkpoint inhibitor therapyElias Haj-Yehia, Raluca I Mincu, Phillip Schulte, et al.
Journal of Visualized Experiments : Jove|October 13, 2025
Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence MicroscopySebastian Korste, Elias Haj-Yehia, Simon F Merz, et al.
Diabetes, Obesity & Metabolism|July 24, 2018
Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacitySebastian Diebold, Julia Moellmann, Florian Kahles, et al.
British Journal of Pharmacology|June 16, 2026
Refining the treatment of immune checkpoint inhibitor-associated myocarditis: Challenges, innovations and rechallenge considerationsRaluca I Mincu, Lisa Zimmer, Dimitra Vlachopoulou, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 13, 2023
High neutrophil-to-lymphocyte ratio is associated with cancer therapy-related cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapyElias Haj-Yehia, Raluca I Mincu, Sebastian Korste, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 29, 2026
Evaluation of neutrophil oxidative burst capacity in relation to major adverse cardiac events and infection in patients with cardiovascular diseaseElias Haj-Yehia, Phillip Schulte, Christian Fehring, et al.
International Journal of Molecular Sciences|April 13, 2023
Anthracycline Therapy Modifies Immune Checkpoint Signaling in the HeartSebastian Korste, Stephan Settelmeier, Lars Michel, et al.
Journal of Clinical Medicine|December 9, 2020
Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial InfarctionElias Haj-Yehia, Robert Werner Mertens, Florian Kahles, et al.
Pageof 2